A5059868848- Diabetes Treatment and Management
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Metabolism, Diabetes, and Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Atrial Fibrillation Management and Outcomes
- Vaccine Coverage and Hesitancy
- Lipoproteins and Cardiovascular Health
- Pancreatic function and diabetes
- Poxvirus research and outbreaks
- Diabetes Management and Research
- Pharmaceutical Economics and Policy
- Heart Failure Treatment and Management
- COVID-19 epidemiological studies
- Bacillus and Francisella bacterial research
- Herpesvirus Infections and Treatments
- Cardiovascular Function and Risk Factors
- Pharmacology and Obesity Treatment
- Healthcare cost, quality, practices
- SARS-CoV-2 detection and testing
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Diet and metabolism studies
- Cardiac Arrhythmias and Treatments
- Viral Infections and Immunology Research
Sapir College
2016-2025
Clalit Health Services
2021-2024
Ben-Gurion University of the Negev
2011-2024
University of Nebraska Medical Center
2024
Community Medical Center
2022-2023
Alzheimer's Association of Israel
2023
Tel Aviv University
2022
The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding effectiveness preventing disease 2019 (Covid-19) outcomes from B.1.1.529 (omicron) are limited.We obtained data for all members Clalit Health Services who were 40 years age or older at start study period and assessed as being eligible to receive therapy during...
The emergence of the B.1.617.2 (delta) variant severe acute respiratory syndrome coronavirus 2 and reduced effectiveness over time BNT162b2 vaccine (Pfizer-BioNTech) led to a resurgence disease 2019 (Covid-19) cases in populations that had been vaccinated early. On July 30, 2021, Israeli Ministry Health approved use third dose (booster) cope with this resurgence. Evidence regarding booster lowering mortality due Covid-19 is still needed.We obtained data for all members Clalit Services who...
The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decreases substantially among patients who have recovered from disease 2019 (Covid-19). However, it is unknown how long protective immunity lasts. Current guidelines recommend vaccination even though data regarding vaccine effectiveness in such cases are still limited.
Importance Evidence regarding the relative effectiveness of bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in reducing mortality major adverse cardiovascular events (MACEs) is limited. Objective To compare all-cause nonfatal MACEs associated with BMS vs GLP-1RAs for adults obesity diabetes without known disease. Design, Setting, Participants This observational, retrospective cohort study was based on data obtained from electronic medical records...
Objective Atrial fibrillation (AF) screening by age achieves a low yield and misses younger individuals. We aimed to develop an algorithm in nationwide routinely collected primary care data predict the risk of incident AF within 6 months (Future Innovations Novel Detection Fibrillation (FIND-AF)). Methods used electronic health record from individuals aged ≥30 years without known UK Clinical Practice Research Datalink-GOLD dataset between 2 January 1998 30 November 2018, randomly divided...
Abstract Objective Higher doses of the glucagon‐like peptide‐1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money this indication is unclear. Methods The cost needed to treat achieve 1% weight using or was calculated. reductions were extracted from published STEP 1 trial and SCALE results, respectively. A scenario analysis performed mitigate primary differences between two studies'...
Higher doses of the glucagon-like peptide-1 agonist semaglutide and, more recently, tirzepatide, a dual glucose-dependent insulinotropic polypeptide and showed significant reduction in body weight patients with type 2 diabetes mellitus. However, their comparative value for money this indication is unclear. Therefore, we aimed to establish which provides better money.We calculated cost needed treat achieve 1% using high-dose tirzepatide (15 mg) versus (2.4 mg). The reductions were extracted...
Evidence regarding the high-dose (HD) vaccine's relative vaccine effectiveness (rVE) and absolute benefit in reducing influenza-related hospitalizations compared to standard-dose (SD) is warranted. We estimated adjusted rVE number needed vaccinate (NNV) of HD SD among Clalit Health Services members aged ≥65 years. Among 418,603 393,125 vaccinated 2022–2023 2023–2024 influenza seasons, was 27% (95% CI: −12% 61%) for 7% −36% 42%) 2023–2024, with NNV prevent one hospitalization event being 2262...
Abstract Background The recent global outbreak of the human monkeypox virus (MPXV) was declared a public health emergency by World Health Organization. Modified Vaccinia Ankara (MVA) is currently only FDA-approved vaccine against MPXV that approved for this indication based on study in non-human primates. Since there scarce evidence efficacy humans, our objective to evaluate real-life effectiveness (VE) after providing one dose individuals at risk MPVX infection. Methods cohort included all...
Background: During Late 2022, the SARS-CoV-2 Omicron BA.5 sublineages accounted for most of sequenced viral genomes worldwide. Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5. Since September a single bivalent booster dose has been recommended adults who have completed primary vaccination series and are at high risk severe Covid-19 disease. Evidence regarding effectiveness vaccine in reducing hospitalizations death due to is warranted.Methods: This...
Background: The increasing burden of atrial fibrillation (AF) emphasizes the need to identify high-risk individuals for enrolment in clinical trials AF screening and primary prevention. We aimed develop prediction models at across horizons from 6-months 10-years. Methods: used secondary-care linked care electronic health record data aged ≥30 years without known UK Clinical Practice Research Datalink-GOLD dataset between Jan 2, 1998 Nov 30, 2018; randomly divided into derivation (80%)...
Measures employed to combat COVID-19 included public lockdowns and vaccination campaigns. Israel’s extensive health system produced data demonstrating the real-world results of these measures. Our objective was evaluate economic outcomes measures cope with COVID-19. Publicly available datasets from Israeli Ministry Health were used model parameters pandemic in Israel. The Oxford Government Response Tracker for quantitative on government policies. Data economy taken Central Bureau Statistics....
Abstract Background Nirmatrelvir, an inhibitor of the main protease severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a significant decrease in risk progression to disease symptomatic high-risk patients infected with B.1.617.2 (delta) variant SARS-CoV-2. The effectiveness nirmatrelvir against B.1.1.529 (omicron) is unknown. Methods study included all Clalit Health Services members, 40 years age and older, confirmed infection SARS-CoV-2 during omicron surge that...
Background and Aim: Dapagliflozin empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving in CKD is unestablished. We examined the cost-per-outcome implications of utilizing dapagliflozin as compared to prevention renal cardiovascular events patients. Methods: For calculation preventable we divided allocated budget by cost needed treat (CNT) preventing a single or event. CNT was...
Abstract Background The oral antiviral molnupiravir is moderately effective in high-risk, unvaccinated non-hospitalized patients infected with early variants of SARS-CoV-2. Data regarding the effectiveness against B.1.1.529 (omicron) variant and vaccinated populations are limited. Methods We obtained data for all members Clalit Health Services, 40 years age older, eligible therapy during omicron surge. A Cox proportional-hazards regression model time-dependent covariates was used to estimate...